speb/financial-data huggingface dataset:
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 88880000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 144690000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Fixed Assets Revaluation Reserve: 78392000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: -11360000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: -850000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 101730000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Goodwill: 300000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 300000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 160540000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Hedging Assets Current: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Held To Maturity Securities: 10179000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Interest Income: 15460000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 15460000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 87590000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 0.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -67880000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 329610000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -67880000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: -67880000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: -67879000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Assets: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 12560000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 23453000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Other Payable: 74960000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 1370000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Other Special Charges: -850000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 4900000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 163610000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 125710000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 24770000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 24770000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Repayment Of Debt: -67880000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 8940000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 693710000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 138790000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 240520000.00
JAGSNPHARM.NS cash_flow (annual, 2022-03-31) — Short Term Debt Payments: -67879000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 240000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 2330000.00
JAGSNPHARM.NS balance_sheet (annual, 2022-03-31) — Work In Process: 27020000.00
JAGSNPHARM.NS income_statement (annual, 2022-03-31) — Write Off: 420000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1098700000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — +Total Revenue: 2367140000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 165800000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 208720000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -85910000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 6000000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -6000000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 33840000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 65495000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Basic EPS: 4.08
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 225260000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 163800000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -3180000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 60010000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 130990000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 110530000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 1147110000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 110530000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 86860000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 62630000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 23600000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Payable: -19620000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -55560000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 94960000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -114730000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock: 130990000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 1588900000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 925140000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Assets: 1645590000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 7540000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 7540000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 275710000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 3755000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Defined Pension Benefit: 20320000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation: 11750000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 11750000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 11750000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 11750000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 65495000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Diluted EPS: 4.08
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 267210000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 0.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — EBIT: 350860000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — EBITDA: 362610000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — End Cash Position: 110530000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -4570000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 117880000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 463370000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -1480000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -3590000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 55930000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 214720000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 328690000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Gross Profit: 1442000000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense: 2780000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 2780000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Interest Income: 34280000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 34280000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -4130000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 34280000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Inventory: 206760000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 1588900000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -576710000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 33840000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 87590000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 52470000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 52470000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 10750000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 18020000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 0.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income: 267210000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 267210000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 267210000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 267210000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 267210000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 348080000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 267210000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Interest Income: 30150000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -620770000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 0.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 0.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 30150000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -3221000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -10000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Net PPE: 242780000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: 9780000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 1588900000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 21630000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 10750000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 3810000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 392130000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Normalized Income: 290401870.26
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 466550000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Operating Income: 343300000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Operating Revenue: 2367140000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 65495000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 80702000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 1400000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 87650000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -2360000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 20323000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 4460000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 185640000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Payable: 85100000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Properties: 59280000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1036580000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Other Special Charges: 31000000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Payables: 251090000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 3760000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 83000000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Pretax Income: 348080000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 4000000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -1058940000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -3180000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 78070000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 925140000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 11750000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 18310000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 18310000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 945370000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 438170000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 12960000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 178730000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 234660000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 65495000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Short Term Debt Payments: 0.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Special Income Charges: -31300000.00
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 87650000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 1588900000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 1588900000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -6928129.74
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Tax Provision: 80870000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.23
JAGSNPHARM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -72760000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 1949460000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 1588900000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 60010000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 1588900000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Total Expenses: 2023840000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 360560000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 303870000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 84850000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 1350000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 190000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -29520000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -29820000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 10810000.00
JAGSNPHARM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 1369880000.00
JAGSNPHARM.NS income_statement (annual, 2023-03-31) — Write Off: 2620000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1069620000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 2087020000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 75960000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 109510000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -11280000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 111200000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -10530000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 171790000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 47000000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 66123628.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Basic EPS: 3.40
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 110530000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 0.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -2480000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 89410000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 132190000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 127600000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 1479340000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -130990000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 70100000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 57500000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 53100000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -33490000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 31870000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Payable: -89820000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 91540000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 55390000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 17070000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 132190000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 1874020000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 56350000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 799770000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 1967790000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 13840000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 13840000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 191280000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 7520000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Defined Pension Benefit: 21060000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation: 16630000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 16630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 16630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 16630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 66299169.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 3.39
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 224630000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 780000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — EBIT: 306830000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — EBITDA: 323460000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 127600000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -89110000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 77090000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 349180000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 0.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 38050000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 120040000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 104300000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Gross Profit: 1285690000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense: 7770000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 7770000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Interest Income: 85920000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 85920000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -8140000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 73670000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Inventory: 149970000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 1874020000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -245480000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 47000000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 56350000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 75570000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 75570000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 9180000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 20380000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 56350000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income: 224630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 224630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 224630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 224630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 224630000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 298690000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 224630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Interest Income: -8140000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -316670000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -8140000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 93020000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -2480000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 1874020000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 20730000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 9180000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 29450000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 323460000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Normalized Income: 224630000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 351660000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Operating Income: 216070000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 2087020000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 66094485.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 80830000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 1050000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 170700000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -77780000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 21060000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 4840000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 223570000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 74190000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 83920000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 1351740000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Payables: 150930000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 7520000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 57180000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Pretax Income: 298690000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 7070000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -1354070000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -2480000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 60240000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 799770000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 16630000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 9130000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 9130000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 1041910000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 1037400000.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 0.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 163360000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 201410000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 66094485.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 0.00
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 133100000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 1874020000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 1874020000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 0.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Tax Provision: 74060000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.25
JAGSNPHARM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -85130000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 2170780000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 1874020000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 89410000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 1874020000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Total Expenses: 1870950000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 296760000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 202990000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 105480000.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 370000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 0.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 0.00
JAGSNPHARM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 12640000.00
JAGSNPHARM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 1776510000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 141210000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 194860000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Assets Held For Sale Current: 171790000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 161630000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 98140000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 132420000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 184410000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 779550000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 132420000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 1971030000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 1387860000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 16160000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 16160000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 469910000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 6320000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 894450000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 99960000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 167980000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 1971030000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 161630000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 81980000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 81980000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 9830000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 99960000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 1076580000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 36430000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 66211527.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 73680000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 171310000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 1838610000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 797520000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 25620000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 99960000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 595140000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 145720000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 66211527.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 1971030000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 1076580000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 2581980000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 1971030000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 98140000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 1971030000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 610950000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 1194120000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 141040000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 4510000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 917950000.00
JAGSNPHARM.NS income_statement (quarterly, 2024-12-31) — Other Special Charges: -231840000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 1293380000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 304310000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 2687160000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 585600000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 97340000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 97340000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 131760000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 131760000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -8660000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 140560000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -7560000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Assets Held For Sale Current: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Assets Held For Sale Current: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 173910000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 173910000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 67023002.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 67173469.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Basic EPS: 8.26
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 0.98
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 127600000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 0.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 0.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -3480000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 92390000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 92390000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 132800000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 132800000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 112150000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 112150000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 1287320000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 1287990000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -132290000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 89470000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 89470000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 10000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 5620000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: 44790000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: 21380000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -22250000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 53370000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -17320000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 132800000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 132800000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 2399500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 2399500000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 33910000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 964380000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 217200000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 1611940000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 1611940000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 16070000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 16070000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 16070000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 16070000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 259040000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 259040000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 10140000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 10140000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Defined Pension Benefit: 18450000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Defined Pension Benefit: 18450000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 81310000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 81310000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 81310000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 23050000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 81310000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 23050000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 67349148.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 67173469.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 8.22
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.98
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 553610000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 65831000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 1870000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 708170000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 89670000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 789480000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 112720000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 110280000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -116980000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 104500000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 547650000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 96930000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 856170000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 856170000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 139320000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 88370000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 88370000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 1722780000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 368400000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 9580000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 2590000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 9580000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 2590000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 76450000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -9580000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 78400000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 152000000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 152000000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 2399500000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 2399500000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -451470000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 173910000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 173910000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 33910000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 0.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 76320000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 76320000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 76320000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 76320000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 6660000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 6660000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 14770000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -936570000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 33910000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 553611000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 65831000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 553611000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 65830000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 553610000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 65830000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 553611000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 65831000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 553611000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 65830000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 698590000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 553610000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 65830000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: -9580000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -2590000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 53000000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -9580000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -2590000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 88370000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 88370000.00
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: 353700000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 1543330000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 1543330000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 30700000.00
JAGSNPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 30700000.00
JAGSNPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 31070000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 592610000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 114840000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 397597094.40
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 67432659.62
JAGSNPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 551130000.00
JAGSNPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 429400000.00
JAGSNPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 64090000.00